MEA Cardiosensor

Do you need a relevant and robust cell model for drug safety testing?
Do you want a more clinically predictive cardiotoxicity assay?

Our Cardiosensor is a reliable and rapid system to test for drug effects on cardiac function, including QT-interval prolongation and arrhythmia in vitro.


Cell systems available:

  • Stem-cell derived cardiomyocytes

  • Primary cardiomyocytes from animal models

The assay is based on the extracellular recording of field action potentials (fAPs) of cardiomyocytes in culture with microelectrode arrays (MEAs). fAPs reflect the concerted activation and inactivation of cardiac ion channels, comparable to an electrocardiogram (ECG) in patients and are thus referred to here as “QT-interval” in vitro.

Drug-induced effects on cardiac function can be observed in our test system, as a prolongation of the fAP duration (“QT-interval in vitro”) and/or arrhythmic beating behavior of the electrically coupled cardiomyocytes.



1. Kraushaar, Udo, and Elke Guenther. "Assay Procedures for Compound Testing of hiPSC-Derived Cardiomyocytes Using Multiwell Microelectrode Arrays." Cell-Based Assays Using iPSCs for Drug Development and Testing. Humana, New York, NY, 2019. 197-208. Link

2. Meyer, Thomas, Elke Guenther, and Udo Kraushaar. "Microelectrode arrays in cardiac mapping." Cardiac Mapping(2013): 18-27. Link

3. Kraushaar, Udo, et al. "Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell-based disease models." Expert opinion on drug safety 11.2 (2012): 285-298. Link

4. Meyer, Thomas, et al. "Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals." Expert opinion on drug metabolism & toxicology 6.12 (2010): 1461-1475. Link